[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588023":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":57,"collaborators":59,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":59,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":59,"enrollmentInfo":69,"targetDuration":59,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":59,"overallStatus":43,"whyStopped":59,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Taichung Veterans General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aspirin arm","ACTIVE_COMPARATOR","Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo",[13],"Drug: Aspirin 81 mg Enteric Coated Tab - 1 tablet",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo arm","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,26],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Aspirin 81 mg Enteric Coated Tab - 1 tablet",[9],[25],"Un-impede E.F.C.",{"type":21,"name":27,"description":11,"armGroupLabels":28,"otherNames":29},"Placebo",[15],[30],"Placebo Tablet",[32],{"name":33,"affiliation":5,"role":34},"Teng-Yu Lee, MD, MBA, PhD","STUDY_CHAIR",[36],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","+886423592525","3301","tylee@vghtc.gov.tw",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":45,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Taichung","Taiwan","40705","TW",{"type":49,"coordinates":50},"Point",[51,52],120.6839,24.1469,{"lat":52,"lon":51},[55],{"name":33,"role":37,"phone":56,"phoneExt":39,"email":40},"0423592525",{"type":58,"investigatorFullName":59,"investigatorTitle":59,"investigatorAffiliation":59,"oldNameTitle":59,"oldOrganization":59},"SPONSOR",null,"100588023","phase-2-aspirin-for-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-100588023",false,"NCT06935994","Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease","Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Diagnosed with MASLD, which is defined by the Delphi consensus, with at least one out of five cardiometabolic criteria\n\nExclusion Criteria:\n\n1. Increased alcohol intake (average ≥ 20 g\u002Fday for women and ≥ 30 g\u002Fday for men)\n2. Glycated hemoglobin (HbA1c) level ≥ 9.0%\n3. Other causes of chronic liver disease, such as HBV, HCV, autoimmune hepatitis, Wilson's disease, etc.\n4. Liver decompensation (Child-Pugh class B or C)\n5. Liver cirrhosis with significant portal hypertension (platelet count \\\u003C 100,000\u002Fmm3, splenomegaly, and\u002For the presence of esophageal\u002Fgastric varices)\n6. High-risk EGV, defined as F2, F3, or with red-color signs, diagnosed by endoscopy within 6 months before screening\n7. Active peptic ulcer disease diagnosed by endoscopy within 6 months be- fore screening\n8. FIB-4 index \\\u003C 1.3 at screening\n9. Indicated for any anti-platelet therapy, such as history of cardiovascular events\n10. History of aspirin allergy\n11. History of bleeding disorders, such as hemophilia\n12. Pregnancy or breast feeding\n13. Severe renal impairment, which is defined as eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n14. Any malignancies","ALL","18 Years",{"count":70,"type":71},120,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and a significant public health issue. MASLD may progress to liver cirrhosis and\u002For hepatocellular carcinoma. Although previous evidence suggests that aspirin has antisteatotic and antifibrotic effects on the liver, a randomized controlled trial assessing long-term efficacy and safety of aspirin in MASLD patients has yet to be conducted. This study aims to conduct a randomized controlled trial to evaluate the efficacy of aspirin in treating MASLD.",[77],"Metabolic Dysfunction Associated Steatotic Liver Disease","2025-05-06",{"date":80,"type":81},"2025-05-11","ACTUAL",{"date":83,"type":81},"2025-05-05",{"date":85,"type":71},"2032-12-31",{"name":5,"class":6},1]